Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial

Diabetes

Volumn 46, Issue 11, 1997, Pages 1829-1839

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHILD PARENT RELATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE SEVERITY; EYE FUNDUS; EYE PHOTOGRAPHY; FAMILIAL DISEASE; FAMILY SIZE; FEMALE; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGENY; RELATIVE; SIBLING;

EID: 0030725948     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.11.1829     Document Type: Article

References (68)

1. DCCT Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:977-986, 1993
2. Seaquist ER, Goetz FC, Rich SS, Barbosa J: Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165, 1989
3. Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH: Is diabetic nephropathy an inherited complication? Kidney Int 41:719-722, 1992
4. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940-945, 1996
5. DCCT Research Group: DCCT Manual of Operations. Springfield, VA, U.S. Dept. of Commerce, National Technical Information Service, 1993 (PB 93-183382)
6. DCCT Research Group: Design and methodologic considerations for the feasibility phase. Diabetes 35:530-545, 1986
7. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS Report #12. Ophthalmology 98:823-833, 1991
8. DERI Mortality Study Group: International evaluation of cause-specific mortality and IDDM. Diabetes Care 14:55-60, 1991
9. Rao JNR, Scott AJ: A simple method for the analysis of clustered binary data Biometrika 48:577-585, 1992
10. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 73:13-22, 1986
11. Zeger SL, Liang K: Longitudinal data analysis for discrete and continuous outcome. Biometrika 42:121-130, 1986
12. Donner A, Koval JJ: The estimation of intraclass correlation in the analysis of family data. Biometrics 36:19-25, 1980
13. Donner A, Koval JJ, Bull S: Testing the effects of sex differences on sib-sib correlations. Biometrics 40:349-356, 1984
14. Donner A, Eliasziw M: Methodology for inferences concerning familial correlation: a review. J Clin Epidemiol 44:449-455, 1991
15. Tambs K, Moum T, Holmen J, Eaves LJ, Neale MC, Lund-Larsen G, Naess S: Genetic and environmental effects on blood pressure in a Norwegian sample. Genet Epidemiol 9:11-26, 1992
16. Moll PP, Burns TL, Lauer RM: The genetic and environmental sources of body mass index variability: the Muscatine Ponderosity Family Study. Am J Hum Genet 49:243-255, 1991
17. Cavalli-Sforza LL, Bodmer WF: The Genetics of Human Populations. San Francisco, W.H. Freeman, 1971, p. 243-255
18. Davis MD: Diabetic retinopathy, a clinical overview. Diabetes Care 15:1844-1874, 1992
19. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjær H, Frøland A, Hansen KW, Nielsen S, Pedersen MM: Microalbuminuria and potential confounders. Diabetes Care 18:572-581, 1995
20. Parving H-H, Gall M-A, Skøtt P, Jørgensen HE, Løkkegaard H, Jørgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin dependent diabetic patients. Kidney Int 41:758-762, 1992
21. Nathan DM: Long-term complications of diabetes mellitus. N Engl Med 328:1676-1685, 1993
22. DCCT Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
23. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 15:815-819, 1992
24. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
25. Hamman RF, Franklin GA, Mayer EJ, Marshall SM, Marshall JA, Baxter J, Kahn LB: Microvascular complications of NIDDM in Hispanics and non-Hispanic whites: San Luis Valley Diabetes Study. Diabetes Care 14:655-664, 1991
26. Kalter-Leibovici O, Van Dyk DJ, Leibovici L, Loya N, Erman A, Kremer I, Boner G, Rosenfeld JB, Karp M, Laron Z: Risk factors for development of diabetic nephropathy and retinopathy in Jewish IDDM patients. Diabetes 40:204-210, 1991
27. Pyke DA, Tattersall RB: Diabetic retinopathy in identical twins. Diabetes 22:613-618, 1973
28. Dornan TL, Ting A, McPherson CK, Peckar CO, Mann JI, Turner RC, Morris PJ: Genetic susceptibility to the development of retinopathy in insulin-dependent diabetics. Diabetes 31:226-231, 1982
29. Cruickshanks KJ, Vadheim CM, Moss SE, Roth M-P, Riley WJ, Maclaren NK, Langfield D, Sparkes RS, Klein R, Rotter JI: Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 years of age. Diabetes 41:879-885, 1992
30. Dhrama SK, Di'Amico DJ: HLA antigens and the development of diabetic retinopathy. Int Ophthalmol Clin 33:93-99, 1993
31. Hawrami K, Mohan R, Mohan V, Hitman GA: A genetic study of retinopathy in South Indian type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:441-444, 1991
32. Stewart LL, Field LL, Ross S, McArthur RG: Genetic risk factors in diabetic retinopathy. Diabetologia 36:1293-1298, 1993
33. Heesom AE, Hibberd ML, Millward A, Demaine AG: Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 46:287-291, 1997
34. n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 44:727-732, 1995
35. Henry DN, Del Monte M, Greene DA, Killen PD: Altered aldose reductase gene regulation in cultured human retinal pigment epithelial cells. J Clinical Inves 91:617-623, 1992
36. Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y: Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 38:255-261, 1995
37. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T: High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 37:328-330, 1994
38. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene T-T, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388, 1994
39. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving H-H: Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene in diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44:489-494, 1995
40. Alcolado JC, Baroni MG, Li SR, Gallon DJ: Genetic variation around the collagen IV 1a gene locus and proliferative retinopathy in type 2 diabetes mellitus. Hum Hered 43:126-130, 1993
41. Chandra T, Lakshmi CN, Padma T, Vidyavathi M, Satapathy M: Haptoglobin phenotypes in diabetes mellitus and diabetic retinopathy. Hum Hered 41:347-350, 1991
42. Mansfield MW, Stickland MH, Carter AM, Grant PJ: Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thrombosis Haemostasis 71:731-736, 1994
43. Nelson RG, Knowler WC, Pettitt DJ, Bennett PH: Kidney diseases in diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. Washington, DC, U.S. Gov't. Printing Office, 1995, p. 349-400 (NIH publ. no. 95-1468)
44. Freedman BI, Tuttle AB, Spray BJ: Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 25:710-713, 1995
45. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC: Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:438-443, 1990
46. Forsblom C, Kanninen T, Lehtovirta M, Kaprio J, Groop L, Botnia Research Team: Is urinary albumin excretion an inherited trait? (Abstract). Diabetologia 38 (Suppl 1):A63, 1995
47. Krolewski AS, Canessa M, Warram JH, Laffel LMB, Christlieb AR, Knowler WC, Rand LI: Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318:140-145, 1988
48. Barzilay J, Warram JH, Bak M, Laffel LMB, Canessa M, Krolewski AS: Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 41:723-730, 1992
49. Freire MBS, Ferreira SRG, Vivolo MA, Oliveira JM, Zanella MT: Familial hypertension and albuminuria in normotensive type I diabetic patients. Hypertension 23 (Suppl. 1):I256-I258, 1994
50. Earle K, Viberti GC: Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int 45:434-437, 1994
51. Jensen JS, Mathiesen ER, Norgaard K, Hommel E, Borch-Johnsen K, Funder J, Brahm J, Parving HH, Deckert T: Increased blood pressure and erythrocyte sodium/lithium countertransport activity are not inherited in diabetic nephropathy. Diabetologia 33:619-624, 1990
52. Fujita J, Tsuda K, Seno M, Obayashi H, Fukui I, Seino Y: Erythrocyte sodium-lithium countertransport activity as a marker of predisposition to hypertension and diabetic nephropathy in NIDDM. Diabetes Care 17:977-982, 1994
53. Houtman PN, Campbell FM, Shah V, Grant DB, Dunger DB, Dillon MJ: Sodium-lithium countertransport in children with diabetes and their families. Arch Dis Child 72:113-136, 1995
54. Elving LD, Wetzels JFM, DePont JJHHM, Berden JHM: Is increased erythrocyte sodium-lithium countertransport a useful marker for diabetic nephropathy? Kidney Int 41:862-871, 1992
55. Earle K, Walker JD, Hill C, Viberti GC: Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 326:673-677, 1992
56. Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy: evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43:690-695, 1994
57. Ohno T, Kawazu S, Tomono S: Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism 45:218-222, 1996
58. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Boelskifte S, Borch-Johnsen K, Parving H-H: Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38:798-803, 1995
59. Hibberd ML, Millward BA, Demaine AG: Angiotensin converting enzyme genotypes and complications in type 1 diabetes (Abstract). Diabetologia 38 (Suppl. A227):878, 1995
60. Chaturvedi N, Talmud P, Fuller JH, EUCLID Study Group: Angiotensin converting enzyme (ACE) gene polymorphisms and complications in insulin dependent diabetes mellitus (IDDM) (Abstract). Diabetologia 38 (Suppl. A227):880, 1995
61. Schmidt S, Schöne N, Ritz E, Diabetic Nephropathy Study Group: Association of ACE gene polymorphism and diabetic nephropathy? Kidney Int 47:1176-1181, 1995
62. Fujisawa T, Ikegami H, Shen G-Q, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J, Ohishi M, Fujii K, Fukuda M, Ogihara T: Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 18:983-985, 1995
63. Chowdhury TA, Dronsfield MJ, Kumar S, Gough SLC, Gibson SP, Khatoon A, MacDonald F, Rowe BR, Dunger DB, Dean JD, Davies SJ, Webber J, Smith PR, Mackin P, Marshall SM, Adu D, Morris PJM, Todd JA, Barnett AH, Boulton AJM, Bain SC: Examination of two genetic polymorphisms within the reninangiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia 39:1108-1114, 1996
64. Fogarty DG, Harron JC, Hughes AE, Nevin NC, Doherty CC, Maxwell AP: A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes 45:1204-1208, 1996
65. Rønningen KS, Bangstad H-J, Undlien DE, Thorsby E: Influence of genetic factors (HLA class II genes, insulin-gene region polymorphisms) and metabolic control on the development of diabetic nephropathy. Diabetes Res 23:31-40, 1993
66. Raffel LJ, Vadheim CM, Roth M-P, Klein R, Moss SE, Rotter JI: The 5′ insulin gene polymorphism and the genetics of vascular complications in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:680-683, 1991
67. Madacsy L, Szorady I, Santa A, Barkai L, Vamosi I: Association of microalbuminuria with slow acetylator phenotype in type 1 diabetes mellitus. Child Nephrol Urol 12:192-196, 1992
68. Neugebauer S, Baba T, Watanabe T, Ishizaki T, Kurokawa K: The N-acetyl-transferase (NAT) gene: an early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients? Diabet Med 11:783-788, 1994